Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Model Service for Gene Therapy (AAV/Lentivirus) Efficacy Optimization
Are you currently facing challenges with inefficient gene delivery, unpredictable immune responses, or difficulty optimizing therapeutic efficacy in your preclinical gene therapy programs? Our NHP Gene Therapy Models service helps you accelerate drug discovery and ensure clinical success through advanced AAV and Lentivirus vector optimization, rigorous delivery studies, and precise immune response monitoring in non-human primates.
Introduction of NHP Gene Therapy Models
NHPs are the gold standard for preclinical gene therapy studies, providing an essential bridge between rodent models and human clinical trials. At Creative Biolabs, we leverage the close biological and genetic similarities of NHPs to humans to create a predictive and reliable model for your research. Unlike other preclinical models, NHPs possess homologous CNS anatomy, brain size, and immune system characteristics, making them uniquely suited for evaluating gene therapy safety and efficacy.
What Our Service Is
Creative Biolabs' NHP Gene Therapy Models service offers a comprehensive platform for the preclinical evaluation of gene therapies, utilizing both Adeno-associated virus (AAV) and Lentivirus vectors. This service is designed to mitigate risk and optimize your therapeutic approach. Application Scenarios:
- Neurological Disorders: We facilitate the evaluation of AAV vectors for targeted delivery to the central nervous system (CNS) to treat conditions such as Huntington's, Alzheimer's, and Parkinson's disease.
- Genetic and Rare Diseases: Our models are used to assess systemic or localized gene delivery for treating inherited conditions like muscular dystrophy or hemophilia.
- Immunological Research: We assist in developing gene therapies that modulate the immune system, such as CAR-T cell therapies or gene editing applications.
Why Choose Us?
The journey from a therapeutic concept to a successful clinical trial is fraught with challenges. Many gene therapies fail due to poor vector tropism, inefficient delivery, or an undesirable immune response. We provide value to our customers by directly addressing these pain points.
-
Pain Point: Inefficient gene delivery and vector biodistribution.
- Benefit: We optimize delivery methods and select the most efficient AAV capsids for your specific target tissue, ensuring maximum therapeutic effect.
-
Pain Point: The immune response to the AAV vector limits long-term expression.
- Benefit: We offer unparalleled expertise in modulating immune responses, using carefully designed immunosuppression regimens to promote long-term transgene expression.
Fig.1 Architecture of the AAV cap gene and approaches for its diversification.1
Key Benefits of Our Service
Our NHP Gene Therapy Models service is built on a foundation of scientific rigor, advanced technology, and a commitment to precision. We provide a competitive edge through several key features that set us apart.
- Unmatched NHP Resources: Our extensive colony of meticulously monitored NHPs ensures the availability of suitable models, accelerating your project timelines and eliminating bottlenecks.
- Rapid Response Time: We have streamlined our processes to provide a quick turnaround for study design, protocol approval, and project initiation.
- Customization: Every project is unique. Our team works closely with you to design a study tailored to your specific therapeutic goals, from vector selection to delivery route and monitoring.
- Advanced Vector Screening: We utilize cutting-edge multiplex barcode rAAV vector-tracing strategies, allowing for the simultaneous comparison of multiple AAV capsids.
- In-Depth Reporting: Our comprehensive data packages provide granular detail on biodistribution, transgene expression, and immunological outcomes, giving you the insights needed to make informed decisions.
How Creative Biolabs' Service Can Assist Your Project?
Our service provides a clear, actionable pathway for your gene therapy project, delivering the data you need to progress with confidence.
01
Required Starting Materials
02
Project Consultation & Study Design
03
Regulatory & Ethical Review
04
In-Life Phase & Gene Delivery
05
Sample Collection & Processing
06
Data Analysis & Final Reporting
Key Deliverables
- Comprehensive Final Report
- Raw Data Files
- High-Resolution Imaging and Histology Slides
- Detailed Model Annotation Sheets
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: What are the key advantages of using NHPs over other models for my gene therapy study?
A: While other models like mice can provide initial proof of concept, NHPs offer a more clinically relevant model due to their genetic, immunological, and physiological similarities to humans. This reduces the risk of unexpected outcomes in clinical trials and provides a more accurate prediction of safety and efficacy. The data from NHP studies are also more compelling for regulatory submissions.
Q: How do you handle potential immune responses that might limit the success of my therapy?
A: We are experts in managing the host immune response. Our approach involves a thorough understanding of the specific vector and transgene, and we employ tailored immunosuppression regimens and monitoring to ensure long-term transgene expression. We can work with you to design a strategy that minimizes immune-mediated rejection and maximizes therapeutic longevity.
Q: What if I'm not sure which AAV serotype or delivery route is best for my project?
A: Our team is here to help! We can use our advanced multiplex vector-tracing strategy to evaluate multiple AAV capsids and delivery routes simultaneously. This systematic approach allows us to pinpoint the optimal combination for your specific target tissue and project goals, saving you time and resources.
Q: Is your service suitable for both AAV and Lentivirus-based gene therapies?
A: Yes. Our expertise extends to both AAV and Lentivirus vectors. We can help you determine the most appropriate vector for your application and design a study protocol that leverages the unique advantages of each system for optimal results.
Q: What kind of information should I provide to get started?
A: To initiate the process, you would typically provide us with your gene sequence, details about your desired vector, and information about the target disease and tissue. Our team will then work with you to design a detailed, customized study protocol. Contact us to discuss your project; we are ready to assist you in every step.
Contact Us
Creative Biolabs is your trusted partner in accelerating gene therapy development. Our commitment to scientific excellence and our comprehensive NHP models and services ensure your project is grounded in reality and poised for clinical success. For detailed information and to discuss your project, please contact our team.
Reference
- Becker, Jonas, Julia Fakhiri, and Dirk Grimm. "Fantastic AAV gene therapy vectors and how to find them—random diversification, rational design and machine learning." Pathogens 11.7 (2022): 756. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/pathogens11070756